Other research analysts have also issued reports about the company. Zacks Investment Research lowered Microbot Medical from a hold rating to a sell rating in a research report on Saturday, November 16th. HC Wainwright restated a buy rating and set a $10.00 target price on shares of Microbot Medical in a research report on Friday, November 22nd.
MBOT traded up $0.05 during trading on Tuesday, reaching $4.92. 17,244 shares of the stock traded hands, compared to its average volume of 31,131. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of 0.02. The stock’s 50-day moving average is $4.96 and its 200 day moving average is $5.53. Microbot Medical has a 12 month low of $1.38 and a 12 month high of $19.40. The stock has a market capitalization of $21.41 million, a PE ratio of -2.04 and a beta of 4.99.
About Microbot Medical
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
Further Reading: Economic Reports
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.